Fjarde AP Fonden Fourth Swedish National Pension Fund Reduces Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Key Points

• The Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its stock holdings in DexCom, Inc. by 15.2%, ending the first quarter with 53,744 shares valued at approximately $3.67 million.
• Institutional investors now own 97.75% of DexCom's stock, with multiple funds either increasing or adjusting their holdings during recent quarters.
• DexCom recently reported strong earnings, beating estimates with $1.16 billion in revenue and a profit of $0.48 EPS, reflecting a 15.2% year-over-year revenue growth.

Fjarde AP Fonden Fourth Swedish National Pension Fund lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 15.2% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 53,744 shares of the medical device company's stock after selling 9,600 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in DexCom were worth $3,670,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Nia Impact Advisors LLC raised its holdings in DexCom by 1.4% in the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after purchasing an additional 140 shares during the period. Wedbush Securities Inc. lifted its stake in DexCom by 1.2% during the first quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock worth $899,000 after purchasing an additional 157 shares in the last quarter. Argonautica Private Wealth Management Inc. lifted its stake in DexCom by 3.2% during the first quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock worth $407,000 after purchasing an additional 182 shares in the last quarter. Personal CFO Solutions LLC lifted its stake in DexCom by 7.3% during the first quarter. Personal CFO Solutions LLC now owns 3,446 shares of the medical device company's stock worth $235,000 after purchasing an additional 234 shares in the last quarter. Finally, SeaCrest Wealth Management LLC raised its stake in shares of DexCom by 5.6% in the first quarter. SeaCrest Wealth Management LLC now owns 4,696 shares of the medical device company's stock valued at $321,000 after acquiring an additional 249 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In related news, EVP Michael Jon Brown sold 500 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $41,400.00. Following the completion of the sale, the executive vice president owned 95,102 shares of the company's stock, valued at $7,874,445.60. This represents a 0.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nicholas Augustinos sold 3,672 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,656 shares of company stock worth $2,412,191 in the last quarter. 0.32% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on DXCM shares. Canaccord Genuity Group reiterated a "buy" rating and issued a $106.00 price objective on shares of DexCom in a research note on Friday, August 1st. Citigroup reissued a "buy" rating and set a $102.00 price target (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Raymond James Financial lifted their price objective on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a report on Thursday, July 31st. Barclays lifted their price objective on DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a report on Wednesday, July 30th. Finally, Truist Financial started coverage on shares of DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, DexCom has an average rating of "Moderate Buy" and an average price target of $99.89.

DexCom Stock Performance

Shares of DXCM stock opened at $80.95 on Friday. The firm has a market capitalization of $31.74 billion, a P/E ratio of 56.22, a P/E/G ratio of 1.70 and a beta of 1.43. The company's fifty day moving average price is $83.05 and its two-hundred day moving average price is $80.05. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the business posted $0.43 EPS. The company's revenue for the quarter was up 15.2% on a year-over-year basis. On average, research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.